Emerald Investment Advisers LLC Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP

Emerald Investment Advisers LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 69,893 shares of the specialty pharmaceutical company’s stock, valued at approximately $5,786,000. Emerald Investment Advisers LLC owned approximately 0.31% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $21,372,000. NFJ Investment Group LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $2,766,000. Virtus Advisers LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $1,183,000. Quartz Partners LLC bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $1,608,000. Finally, Aurora Investment Counsel purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth $2,226,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ANIP has been the topic of several research reports. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group dropped their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.

Insider Activity

In other news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the transaction, the vice president owned 74,424 shares of the company’s stock, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the transaction, the senior vice president directly owned 75,534 shares in the company, valued at approximately $5,816,118. The trade was a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 18,987 shares of company stock valued at $1,546,405. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Down 2.5%

ANI Pharmaceuticals stock opened at $75.35 on Friday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The firm has a market cap of $1.73 billion, a P/E ratio of 16.24 and a beta of 0.44. The business has a fifty day moving average of $80.36 and a two-hundred day moving average of $78.88. ANI Pharmaceuticals, Inc. has a twelve month low of $70.15 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business’s revenue was up 25.8% compared to the same quarter last year. During the same period last year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.